<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892022000300009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Leucemia promielocítica: enfoques oncogenéticos y moleculares en la era de la medicina de precisión]]></article-title>
<article-title xml:lang="en"><![CDATA[Promyelocytic leukemia: oncogenetic and molecular approaches in the precision´s medicine era]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barroso Sánchez]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Padrón]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garrote Santana]]></surname>
<given-names><![CDATA[Heidys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Hematología e Inmunología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>38</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892022000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892022000300009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892022000300009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El estudio de la patogenia molecular de la leucemia promielocítica revolucionó las bases de la medicina personalizada al identificar la oncoproteína PML/RAR&#945; como diana de terapias dirigidas al mecanismo oncogenético fundador de la enfermedad. Sin embargo, en las últimas décadas, se realizaron otros descubrimientos que aportan mayor información acerca de su biogénesis y desarrollo y el impacto potencial de los mismos en la implementación de técnicas de diagnóstico y herramientas pronósticas como expresión del rápido perfeccionamiento de la medicina traslacional.  Objetivo: Exponer los principales descubrimientos en los mecanismos oncogenéticos y moleculares de actualidad en la leucemia promielocítica.  Métodos: Se realizó una búsqueda exhaustiva en bases de datos como Scielo, Pubmed, ScienceDirect, Redalyc, Google académico. Se utilizaron como referencias los artículos actualizados publicados en los últimos 5 años en idioma inglés y español. Se efectuó un análisis y resumen de la bibliografía y se tomaron los aspectos más importantes referidos al tema.  Análisis y síntesis de la información: Se abordaron los principales aportes de la biología molecular al conocimiento del origen de ésta enfermedad, más allá del enfoque clásico basado en el gen PML/RAR&#945;, así como sus variantes y otros aspectos de interés en su monitorización.  Conclusiones: Las características genéticas de esta enfermedad evidencian un paisaje mutacional diferente al de otras neoplasias mieloides malignas y señalan con especial énfasis la importancia de la integración clínico-biológica para facilitar, perfeccionar y desarrollar el proceso de atención integral a los pacientes con hemopatías malignas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: The study of the molecular pathogenesis of promyelocytic leukemia revolutionized the foundations of personalized medicine by identifying the PML/RAR&#945;oncoprotein as a target for therapies directed at the founding oncogenetic mechanism of the disease. However, in recent decades, other discoveries that provide more information about their biogenesis and development, and their potential impact on the implementation of diagnostic techniques and prognostic tools as an expression of the rapid improvement of translational medicine.  Objective: To expose the main discoveries in the current oncogenetic and molecular mechanisms in promyelocytic leukemia.  Methods:  An exhaustive search was carried out in databases such as Scielo, Pubmed, ScienceDirect, Redalyc, Google Scholar, and updated articles published in the last 5 years in English and Spanish were used as references. An analysis and summary of the bibliography was carried out and the most important aspects related to the subject were taken.  Analysis and synthesis of information:  the main contributions of molecular biology to the knowledge of the origin of this entity were addressed, beyond the classical approach based on the PML/RAR&#945; gene, as well as its variants and other aspects of interest in the monitoring of the illness.  Conclusions:  The genetic characteristics of this disease show a mutational landscape different from that of other malignant myeloid neoplasms and point out with special emphasis the importance of clinical-biological integration to facilitate, improve and develop the comprehensive care process for patients with malignant blood diseases.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[leucemia promielocítica]]></kwd>
<kwd lng="es"><![CDATA[biología molecular]]></kwd>
<kwd lng="es"><![CDATA[genética]]></kwd>
<kwd lng="en"><![CDATA[promyelocytic leukemia]]></kwd>
<kwd lng="en"><![CDATA[molecular biology]]></kwd>
<kwd lng="en"><![CDATA[genetics]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Promyelocytic Leukemia: A Summary]]></article-title>
<source><![CDATA[J Adv Pract Oncol]]></source>
<year>2018</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>178-87</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noguera]]></surname>
<given-names><![CDATA[NI]]></given-names>
</name>
<name>
<surname><![CDATA[Catalano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Banella]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Divona]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faraoni]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ottone]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment Strategies]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2019</year>
<volume>11</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liquori]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ibañez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sargas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Barragán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cervera]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barroso Sánchez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández Padrón]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terapia dirigida a dianas moleculares: perspectiva actual en la leucemia promielocítica]]></article-title>
<source><![CDATA[Rev cubana Hematol Inmunol Hemoter]]></source>
<year>2021</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jimenez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chale]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Abad]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Schally]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute promyelocytic leukemia (APL): a review of the literature]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2020</year>
<volume>11</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>992-1003</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment]]></article-title>
<source><![CDATA[Curr Genomics]]></source>
<year>2017</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>378-84</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Kao]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PML: Regulation and multifaceted function beyond tumor suppression]]></article-title>
<source><![CDATA[Cell Biosci]]></source>
<year>2018</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Thé]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pandolfi]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Promyelocytic Leukemia A Paradigm for Oncoprotein-Targeted Cure]]></article-title>
<source><![CDATA[Cancer cell]]></source>
<year>2017</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>552-60</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cingam]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Koshy]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Promyelocytic Leukemia (APL, APML)]]></article-title>
<source><![CDATA[StatPearls Treasure Island (FL)]]></source>
<year>2022</year>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geoffroy]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[de Thé]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classic and VariantsAPLs, as Viewed from a Therapy Response]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muhsen]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
<name>
<surname><![CDATA[Barragán]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Mohty]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hashmi]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants]]></article-title>
<source><![CDATA[Hematol Oncol Stem Cell Ther]]></source>
<year>2020</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>189-201</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sobas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Talarn-Forcadell]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cuadrón]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PLZF-RAR&#945;, NPM1-RAR&#945;, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moosavi]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Djavaheri-Mergny]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2019</year>
<volume>20</volume>
<numero>14</numero>
<issue>14</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boulanger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paolillo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Piechaczyk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bossis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SUMO Pathway in Hematomalignancies and Their Response to Therapies]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2019</year>
<volume>20</volume>
<numero>16</numero>
<issue>16</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picharski]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Fabro]]></surname>
<given-names><![CDATA[ALMR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2019</year>
<volume>11</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coccaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tota]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Anelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zagaria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Specchia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Albano]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Digital PCR: A ReliableTool for Analyzing and MonitoringHematologicMalignancies]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2020</year>
<volume>21</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cilloni]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Petiti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rosso]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Andreani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dragani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fava]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Digital PCR in Myeloid Malignancies: ¿Readyto ReplaceQuantitative PCR?]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2019</year>
<volume>20</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
